FHL1: A novel diagnostic marker for papillary thyroid carcinoma.

Yeting Zeng, Dehua Zeng, Xingfeng Qi, Hanxi Wang, Xuzhou Wang, Xiaodong Dai, Lijuan Qu
Author Information
  1. Yeting Zeng: Department of Pathology, Joint Logistic Support Force 900th Hospital, Fuzhou, China. ORCID
  2. Dehua Zeng: Department of Pathology, Joint Logistic Support Force 900th Hospital, Fuzhou, China.
  3. Xingfeng Qi: Department of Pathology, Joint Logistic Support Force 900th Hospital, Fuzhou, China.
  4. Hanxi Wang: Department of clinical pathology, Medical Research Center, Fujian Medical University, Fuzhou, China.
  5. Xuzhou Wang: Department of Pathology, Joint Logistic Support Force 900th Hospital, Fuzhou, China.
  6. Xiaodong Dai: Department of Pathology, Joint Logistic Support Force 900th Hospital, Fuzhou, China.
  7. Lijuan Qu: Department of Pathology, Joint Logistic Support Force 900th Hospital, Fuzhou, China.

Abstract

Although there are clear morphologic criteria for the diagnosis of papillary thyroid carcinoma (PTC), when the morphology is untypical or overlaps, accurate diagnostic indicators are necessary. Since few studies investigated the role of down-regulated genes in PTC, this article aims to further explore the molecular markers associated with PTC. We conducted bioinformatics analysis of gene microarrays of PTC and normal adjacent tissues. Besides, quantitative real-time quantitative polymerase chain reaction array and immunohistochemical staining were used to investigate the expression of the major down-regulated genes. The results indicated that several important down-regulated genes, including TLE1, BCL2, FHL1, GHR, KIT, and PPARGC1A were involved in the process of PTC. Compared to normal adjacent tissues, the mRNA expression of the major genes was down-regulated in PTC (p<0.05). Immunohistochemically, FHL1 shows negative or low expression in PTC tissues (p<0.05). BCL2 did not show a significant difference between PTC and normal thyroid tissues (p > 0.05). TLE1, KIT, PPARGC1A and GHR showed negative expression in both tumor and normal tissues. These results suggested that FHL1 could serve as a novel tumor marker for precise diagnosis of PTC.

Keywords

References

  1. Cancers (Basel). 2023 Dec 25;16(1): [PMID: 38201541]
  2. J Pathol Transl Med. 2024 Mar;58(2):98-101 [PMID: 38499006]
  3. Cureus. 2021 Dec 10;13(12):e20339 [PMID: 34934597]
  4. Cancer Res Treat. 2017 Oct;49(4):906-914 [PMID: 28052655]
  5. PLoS One. 2017 Mar 16;12(3):e0173913 [PMID: 28301608]
  6. Mol Cell Biochem. 2012 Apr;363(1-2):93-9 [PMID: 22143536]
  7. PLoS One. 2014 Oct 01;9(10):e108708 [PMID: 25272045]
  8. Mol Med Rep. 2015 Sep;12(3):3958-3964 [PMID: 26017856]
  9. Folia Histochem Cytobiol. 2016;54(4):193-201 [PMID: 28051274]
  10. Cell. 2014 Oct 23;159(3):676-90 [PMID: 25417114]
  11. Head Neck Pathol. 2011 Mar;5(1):51-6 [PMID: 21221869]
  12. Oncol Lett. 2020 Nov;20(5):161 [PMID: 32934729]
  13. J Assist Reprod Genet. 2015 Aug;32(8):1277-84 [PMID: 26115720]
  14. Int J Clin Exp Med. 2014 Aug 15;7(8):2304-8 [PMID: 25232425]
  15. Mol Med Rep. 2015 Aug;12(2):1857-67 [PMID: 25873351]
  16. Cancer Res. 2003 Apr 1;63(7):1454-7 [PMID: 12670889]
  17. Biochem Biophys Res Commun. 2017 May 13;486(4):898-903 [PMID: 28342873]
  18. N Engl J Med. 2016 Sep 15;375(11):1054-67 [PMID: 27626519]
  19. J Exp Clin Cancer Res. 2015 Feb 12;34:16 [PMID: 25887589]
  20. Int J Clin Exp Med. 2015 Nov 15;8(11):20965-70 [PMID: 26885026]
  21. Gene. 2015 Nov 1;572(1):1-7 [PMID: 26211626]
  22. Hum Pathol. 2008 Nov;39(11):1656-63 [PMID: 18657294]
  23. Pathol Int. 2024 Sep;74(9):520-529 [PMID: 39119938]
  24. Clin Exp Otorhinolaryngol. 2019 May;12(2):224-230 [PMID: 30531651]
  25. Neoplasia. 2004 Jan-Feb;6(1):1-6 [PMID: 15068665]
  26. Int J Cancer. 2012 Jun 1;130(11):2549-56 [PMID: 21702045]
  27. Med J Islam Repub Iran. 2023 Mar 20;37:25 [PMID: 37180862]
  28. Pathol Res Pract. 2017 May;213(5):509-517 [PMID: 28214214]
  29. J Clin Pathol. 2010 Sep;63(9):786-9 [PMID: 20644217]

Grants

  1. 2015ZDZKBL/Fujian Province clinical key specialty construction project

MeSH Term

Humans
Biomarkers, Tumor
Thyroid Neoplasms
Thyroid Cancer, Papillary
LIM Domain Proteins
Male
Female
Intracellular Signaling Peptides and Proteins
Muscle Proteins
Middle Aged
Adult
Aged
Gene Expression Regulation, Neoplastic
Immunohistochemistry
Carcinoma, Papillary

Chemicals

Biomarkers, Tumor
LIM Domain Proteins
FHL1 protein, human
Intracellular Signaling Peptides and Proteins
Muscle Proteins

Word Cloud

Created with Highcharts 10.0.0PTCtissuesdown-regulatedgenesnormalexpressionFHL1thyroid05diagnosispapillarycarcinomadiagnosticbioinformaticsanalysisadjacentquantitativemajorresultsTLE1BCL2GHRKITPPARGC1Ap<0negativetumornovelmarkerAlthoughclearmorphologiccriteriamorphologyuntypicaloverlapsaccurateindicatorsnecessarySincestudiesinvestigatedrolearticleaimsexploremolecularmarkersassociatedconductedgenemicroarraysBesidesreal-timepolymerasechainreactionarrayimmunohistochemicalstainingusedinvestigateindicatedseveralimportantincludinginvolvedprocessComparedmRNAImmunohistochemicallyshowslowshowsignificantdifferencep > 0showedsuggestedservepreciseFHL1:biomarkerdown‐regulatedDEGs

Similar Articles

Cited By